Vical’s vaccine has showed preclinical results with 100% response against A/H1N1 pandemic influenza (swine flu), the company claims. The study enrolled mice and rabbits, where the subjects were vaccinated with a standard two-dose vaccine regimen.
At least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. The company said that it is now ready to start large-scale cGMP manufacturing of the vaccine for human clinical trials.
Vijay Samant, President and CEO of Vical, said: The speed of our platform both in development and manufacturing was demonstrated by our rapid completion of vaccine production and successful immunogenicity testing in animals while conventional vaccine manufacturers are still working toward production of their initial supply of H1 vaccine. We are encouraged by these compelling data with our Vaxfectin-formulated DNA vaccine and we look forward to advancing to human clinical trials as soon as possible.